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Abstract
Background: Müllerian aplasia (MA) characterized by congenital loss of functional uterus and vagina is one of the
most difficult disorders of female reproductive health. Despite of growing interest in this research field, the cause
of the disorder for the majority of patients is still unknown. A recent report of partial SHOX duplications in five
patients with MA has motivated us to further evaluate their role in the disorder. Therefore we have studied SHOX
copy number variations (CNVs) in a cohort of 101 Finnish patients with MA and in 115 healthy controls.
Methods: We used multiplex ligation-dependent probe amplification (MLPA) to study SHOX CNVs.
Results: All patients showed normal amplification of SHOX. Several aberrations, duplications and deletions, were
found downstream of the gene in five patients and seven controls, but these were all copy number
polymorphisms.
Conclusions: Our study in an extensive cohort of patients with MA does not support a role for SHOX CNVs in the
aetiology of the disorder. Further studies in the field are important for both patients looking for answers as well as
for the scientific community for better understanding the regulation of the female reproductive duct development.
Background
The Müllerian ducts form the primordial basis for the
female reproductive tract. They differentiate into the
oviducts, uterus, and the upper two-thirds of the vagina
during early embryonic development. A wide variety of
malformations can occur if this development is dis-
rupted. One such malformation is Müllerian aplasia
(MA), also referred to as Mayer-Rokitansky-Küster-Hau-
ser (MRKH, Online Mendelian Inheritance in Man
[OMIM] #277000) syndrome or MURCS assosciation
(Müllerian duct aplasia, Renal dysplasia and Cervical
Somite anomalies, OMIM #601076) as renal and skeletal
malformations are relatively common in patients with
MA [1]. Women with MA are otherwise healthy with
normal female chromosome constitution (46, XX) and
normal secondary sexual characteristics. MA is com-
monly diagnosed in young adulthood due to primary
amenorrhoea. The effects on sexual life with infertility
often cause lifelong psychosocial problems making MA
one of the most difficult disorders of female reproduc-
tive health. The minimum incidence of MA is 1 in 5000
newborn girls [2], and for the majority of the patients
the cause is still unknown.
During recent years, an increasing number of studies
have aimed at investigating the genetic basis of MA. To
date, only mutations in WNT4 (the wingless-type
MMTV integration site family, member 4 gene) have
been reported to cause MA [3-6]. However, the pheno-
type of the four patients with WNT4 mutations includes
hyperandrogenism, which usually is not associated with
MA, suggesting that these patients form a distinct sub-
class of MA (OMIM #158330). Several other candidate
genes involved in fetal development and sex differentia-
tion have been thoroughly investigated without further
success as reviewed by Sultan and colleagues [7].
Chromosomal imbalances studied by array compara-
tive genomic hybridization (aCGH) have been reported
for several chromosomal areas in MA patients [8-14].
However, as these are located in several different loca-
tions along the genome (1q21.1, 16p11.2, 17q12,
22q11.2 and Xq21.31), they have not revealed strong
candidate regions or genes for MA. Interestingly, partial
duplications of SHOX (short stature homeobox gene)
were recently reported in five patients (two sporadic,
three familial) with MA [15]. In one family, the same
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their healthy father, but absent in two healthy sisters
and their mother suggesting a dominant inheritance of
MA from an unaffected male carrier.
SHOX is a homeobox gene covering 40 kb on the
pseudoautosomal region (PAR1) of the X (Xp22) and Y
(Yp11.3) chromosomes. Like other genes within the
PAR1, SHOX escapes X inactivation and therefore both
alleles are normally expressed in males and females.
Mutations and deletions in SHOX have been reported to
cause short stature in patients with idiopathic short sta-
ture (ISS, OMIM #300582), Turner syndrome [16,17],
dyschondrosteosis (Leri-Weill syndrome, LWD, OMIM
#127300) [18] and its more severe form Langer
mesomelic dysplasia (OMIM #249700) [19]. Recently,
some patients with ISS and LWD have been reported to
carry duplications of SHOX/PAR1 region [20].
To further evaluate the role of SHOX in MA, we have
studied SHOX with MLPA (multiplex ligation-dependent
probe amplification) in a cohort of 101 Finnish patients
with MA and 115 healthy female controls.
Patients and methods
Patients
Patients with MA were recruited to the study through the
Departments of Obstetrics and Gynecology of the five
University Hospitals in Finland from year 1978 onwards.
The cohort included 101 Finnish patients, of whom two
are siblings. The clinical phenotype of all patients
includes congenital loss of the uterus and the upper two-
thirds of the vagina, while the status of the oviducts is
not known for all patients. The patients were otherwise
healthy females with a normal female chromosome con-
stitution, hormonally active functioning ovaries, and nor-
mal secondary sexual characteristics. One hundred and
fifteen women with at least one normal pregnancy served
as controls. Informed consent was obtained from all
patients and controls before recruitment. The study pro-
tocol has been approved by the Ethics Committee of the
Department of Obstetrics and Gynecology, Helsinki Uni-
versity Central Hospital, Finland, and the Finnish Minis-
try of Social Affairs and Health.
Sample preparation
DNA from the patients and controls was extracted from
peripheral blood samples using the Puregene DNA Isola-
tion Kit (Gentra Systems, Minneapolis, MN, USA), or by
the phenol-chloroform method. The quality and quantity
of DNA was analyzed by NanoDrop ND-1000 spectrophot-
ometer (Thermo Fisher Scientific, Waltham, MA, USA).
Multiplex ligation-dependent probe amplification (MLPA)
The commercial SALSA MLPA kit PO18-E1 SHOX
(MRC-Holland, Amsterdam, Netherlands) was used for
the amplification reactions according to the manufac-
turer’s recommendation. The MLPA mix included
probes for each exon of SHOX,o n ep r o b ej u s tb e f o r e
the promoter region as well as probes covering a region
downstream of the gene. In short, 100 or 200 ng of
DNA was denatured and incubated with the MLPA
probes for 16-18 h in 60°C. The probes were ligated to
the DNA and amplified by PCR. Thereafter, the PCR
products were visualized on an agarose gel (1.5%, Bio-
line, London, UK), appropriately diluted and combined
with 1% formamide (Applied Biosystems, Foster City,
CA, USA) and GeneScan™-500 LIZ™ size standard
(Applied Biosystems). The products were then separated
by capillary electrophoresis on an ABI3730XL DNA
Analyzer (Applied Biosystems). The results were ana-
lyzed by GeneMapper software version 4.0 (Applied Bio-
systems) and MRC Coffalyzer MLPA-Dat Software
(MRC-Holland). The results were also verified by the
following calculation. Each peak area was divided by the
sum of all peak areas, and the quotient was further
divided by the sum of all peak areas of the reference
sample. A reduction or increase of 40% or more in peak
area, when compared to normal controls, was taken as
suggestive for an aberrant amplification. All aberrant
results were confirmed by a second independent MLPA
analysis.
Results
All investigated MA samples (N = 101) showed normal
amplification of SHOX by MLPA. Aberrant amplification
of some probes downstream of SHOX was detected in
five MA and seven control samples (examples of the
MLPA results are presented in Figure 1). One patient
sample and one control showed two copy number varia-
tions (CNVs), all others samples showed one aberration
each. One larger duplication spanning eleven probes
from 13296-L15336 in Xp22.32-PAR1 to 13911-L16505
in the CRLF2 gene (about 620 kb) was seen in one con-
trol sample (Table 1).
Discussion
The recent findings of partial SHOX duplications in
three familial and two sporadic cases of MA [15] has
motivated us to evaluate their occurrence in a larger
patient cohort. We investigated 101 well-characterized
Finnish MA patients and 115 controls by the MLPA
technique without identifying any SHOX aberrations
that could be interpreted as causative. We did observe
copy number changes in twelve samples (five patients,
seven controls) downstream of SHOX (Table 1), a region
k n o w nt ob ei n v o l v e di nt h eg e n er e g u l a t i o n[ 2 1 , 2 2 ] .
However, these changes were all reported in the Data-
base of Genomic Variants (DGV, http://projects.tcag.ca/
variation) and three of them by Gervasini et al. [15] as
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C. Control with one Xp22.32-PAR1 deletion
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B. Patient without CNVs
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A. Patient with two Xp22.32-PAR1 duplications
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D. Control without CNVs
Figure 1 Examples of the MLPA results. Four examples of MLPA results illustrating A) a patient with duplication identified with two probes in
the Xp22.32-PAR1 region, B) a patient without copy number variations (CNVs), C) a healthy control with a deletion in the Xp22.32-PAR1 region,
and D) a healthy control without identified CNVs.
Table 1 Genomic aberrations found in patients with Müllerian aplasia and in healthy controls.
Region/gene Aberration MLPA probe Cases Controls Reference
Xp22.32-PAR1 Gain 09335-L15508
a 1* 1* DGV
b, Gervasini et al, 2010
Xp22.32-PAR1 Loss 09335-L15508 1 1 DGV
Xp22.32-PAR1 Gain 14697-L16348
a 1* 1* DGV, Gervasini et al, 2010
Xp22.32-PAR1 Loss 14697-L16348 1 DGV
Xp22.32-PAR1
to CRLF2
Gain 13296-L15336 -13911-L16505 1 all 11 probes reported in DGV
CSF2RA Gain 10251-L15502 2 DGV
IL3RA Gain 13597-L15055 1 DGV
ASMT Gain 01153-L00712
c 2 1 DGV, Gervasini et al, 2010
Genomic aberrations found downstream of SHOX (short stature homeobox gene) by multiplex ligation-dependent probe amplification (MLPA, SALSA PO18-E1
SHOX) in 101 Finnish patients with Müllerian aplasia and in 115 healthy controls. One patient sample and one control sample had two copy number variations
(CNVs)*, all other samples had one CNV each.
a the probe sequence is partly overlapping with one MLPA probe (5650-L5104) from version PO18-B SHOX used by Gervasini et al, 2010.
b DGV (Database of Genomic Variants, http://projects.tcag.ca/variation)
c the probe sequence covers the same genomic region as one MLPA probe (1153-L0712) from version PO18-B SHOX used by Gervasini et al, 2010.
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Page 3 of 5harmless CNVs without phenotypic effect. A duplication
5’of SHOX spanning about 620 kb from Xp22.32-PAR1
to the CRLF2 gene was found in one control sample.
The entire duplication is not reported in DGV, but the
genomic sequences of all eleven probes within the dupli-
cation are noted as known copy number variants.
In the study by Gervasini et al. 3/3 familial cases and
2/27 sporadic cases (7%) of MA showed partial duplica-
tions of SHOX. The clinical phenotype of these patients
fulfills the same criteria as defined in our study cohort:
absence of vagina and functional uterus in otherwise
healthy females. If the inheritance of SHOX duplications
in MA is dominant, as suggested, and based on above-
mentioned percentages we would expect several patients
with SHOX duplications in the Finnish cohort (two sis-
ters and seven of the sporadic patients). However, by
implementing the same method as Gervasini and cowor-
k e r si nam o r et h a nt h r e et i m e sl a r g e rp a t i e n tc o h o r t ,
we did not find any aberrations in SHOX suggesting
that SHOX duplications are not a major cause of MA.
Point mutations in SHOX resulting in a gain-of-function
situation cannot, however, be excluded by the MLPA
method.
Overall, duplications of the SHOX gene are rarely
described in the literature. SHOX is thought to regulate
human skeletal growth, and deletions of the gene to
result in short stature (as in Turner syndrome) and an
extra copy in tall stature (as in sex chromosome triso-
m i e s ) .T h ef i r s tc a s eo fSHOX duplication, not reported
in conjunction with a larger chromosome aberration,
was a female with isolated Madelung deformaties of the
wrists. Interestingly, the duplication was also present in
her healthy sister, making the clinical significance of the
duplication unclear [23]. Subsequently, four more
r e p o r t so fp a t i e n t sw i t hSHOX duplications were pub-
lished [20,24-26]. Unfortunately, the status of the uterus
and vagina of the patients was not described in these
reports. Furthermore, SHOX duplication in conjunction
with chromosomal deletions on the long arm of X (Xq)
has been reported in four females [27-30], one of whom
had been reported with premature ovarian failure [30].
The authors suggested that the duplication in this
patient could be involved in the ovarian insufficiency.
The presence of uterus was described for three of the
patients [27,29,30], of whom one had experienced an
early spontaneous abortion [30]. Unfortunately the sta-
tus of uterus and vagina was not described in the fourth
patient [28].
Conclusions
Taken together, there is no clear evidence in the litera-
ture for a role for SHOX in the development of the
female reproductive duct. Secondly, our result based on
an extensive series of Finnish patient samples does not
support SHOX duplications as a frequent cause of MA.
Finally, the duplications of SHOX found by Gervasini
and co-workers [15] in combination with MA can be
coincidental and may not be a reflection of an underly-
ing genetic relationship. However, the aetiology of MA
points to multifactorial inheritance. Partial duplications
of SHOX might therefore be one of several genetic
causes that contribute to the development of MA. Popu-
lation genetic differences could explain why no duplica-
tions of SHOX were found in the Finnish cohort
compared to the Italian. Furthermore, the possibility of
point mutations in SHOX resulting in a gain-of-function
situation cannot be excluded in our study.
Further studies aiming at revealing the genetic and
molecular background of MA are important for both
patients looking for an explanation for their symptoms
as well as for the scientific community. Understanding
the molecular basis of MA will be critical in increasing
o u rk n o w l e d g ef o rt h er e g u l a t i o no ft h ef e m a l er e p r o -
ductive tract development.
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